Online citations, reference lists, and bibliographies.
← Back to Search

Encapsulation Of Vasoactive Intestinal Peptide Into Liposomes: Effects On Vasodilation In Vivo.

H. Suzuki, Y. Noda, S. Paul, X. Gao, I. Rubinstein
Published 1995 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The purpose of this study was to determine whether encapsulation of vasoactive intestinal peptide (VIP) into liposomes potentiated its vasorelaxant effects in vivo. Using intravital microscopy, we measured the diameter of second-order arterioles (53 +/- 1 microns) in the hamster cheek pouch before, during and after suffusion of VIP, liposomes and VIP encapsulated into liposomes for 7 min. We found that VIP (0.05, 0.1 & 1.0 nmol) induced significant, time- and concentration-dependent vasodilation (9 +/- 1%, 13 +/- 3% and 14 +/- 1% increase from baseline values, respectively; mean +/- SEM; n = 12; p < 0.05). Arteriolar diameter returned to baseline values within 1-4 min after suffusion was stopped. These effects were significantly potentiated when VIP (0.05, 0.1 & 1.0 nmol) was encapsulated into liposomes (26 +/- 6%, 38 +/- 7% and 34 +/- 3% increase from baseline values, respectively; n = 12; p < 0.05). In addition, arteriolar diameter returned to baseline values 5-13 min after suffusion was stopped. Suffusion of liposomes alone had no significant effects on arteriolar diameter (n = 12; p > 0.5). We conclude that encapsulation of VIP into liposomes potentiates and prolongs of its vasorelaxant effects in the peripheral microcirculation in vivo.
This paper references
10.1016/0304-3940(89)90396-0
Vagal vasodilatory mechanisms in the pig bronchial circulation preferentially involves sensory nerves
Claes-Roland Martling (1989)
Ph
李幼升 (1989)
10.1002/BIP.360210615
Lipid‐induced conformational changes in glucagon, secretin, and vasoactive intestinal peptide
R. M. Robinson (1982)
10.1021/BI00421A028
Development of helix-based vasoactive intestinal peptide analogues: identification of residues required for receptor interaction.
G. Musso (1988)
10.1111/j.1476-5381.1991.tb12325.x
Endothelium‐dependent and endothelium‐independent vasodilatation of the hepatic artery of the rabbit
A. L. Brizzolara (1991)
10.1016/0969-8051(94)90166-X
In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera.
M. Hassan (1994)
10.1016/S1043-2760(05)80006-2
Vasoactive intestinal polypeptide biologic role in health and disease
S. Said (1991)
10.1126/SCIENCE.2727702
Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody.
S. Paul (1989)
10.1152/JAPPL.1995.78.2.562
Neutral endopeptidase modulates substance P-induced vasodilation in vivo.
X. Gao (1995)
10.1111/j.1440-1681.1994.tb02517.x
EFFECT OF NEUTRAL ENDOPEPTIDASE ON PLASMA AND TISSUE CONCENTRATIONS OF VASO‐ACTIVE INTESTINAL PEPTIDE
K. Duggan (1994)
10.1161/01.RES.68.1.100
Neuropeptide control of rat gastric mucosal blood flow. Increase by calcitonin gene-related peptide and vasoactive intestinal polypeptide, but not substance P and neurokinin A.
P. Holzer (1991)
10.1016/0002-9149(87)90619-9
Cardiovascular effects of vasoactive intestinal peptide in healthy subjects.
L. L. Frase (1987)
L-arginine dilates cheek pouch arterioles in hamsters with hereditary cardiomyopathy but not in controls.
I. Rubinstein (1995)



This paper is referenced by
10.1016/S0076-6879(05)91021-5
Liposomal vasoactive intestinal peptide.
V. Sethi (2005)
10.1016/j.peptides.2004.10.016
All d-VIP mitigates vasodilation elicited by l-VIP, micellar l-VIP and micellar PACAP1–38, but not PACAP1–38, in vivo
I. Rubinstein (2005)
10.1007/s12031-008-9087-1
Inhibitory Effect of PACAP on Caspase Activity in Neuronal Apoptosis: A Better Understanding Towards Therapeutic Applications in Neurodegenerative Diseases
A. Dejda (2008)
10.1517/17425247.2012.735658
Liposomal delivery of proteins and peptides
Janani Swaminathan (2012)
10.1038/s41392-019-0068-3
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Akhand Pratap Singh (2019)
10.1152/JAPPLPHYSIOL.00277.2002
Phospholipids modulate the biophysical properties and vasoactivity of PACAP-(1--38).
Takaya Tsueshita (2002)
10.1152/ajpregu.1998.275.2.R588
Liposomal VIP attenuates phenylephrine- and ANG II-induced vasoconstriction in vivo.
H. Ikezaki (1998)
10.1152/ajpregu.1999.276.5.R1359
Exogenous calmodulin potentiates vasodilation elicited by phospholipid-associated VIP in vivo.
Hiroyuki Ikezaki (1999)
10.1007/s00392-002-0815-1
Effects of adrenomedullin on vascular calcification in rats
B. Zhang (2002)
10.1152/ajpregu.1998.275.1.R56
Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch.
H. Ikezaki (1998)
10.1023/A:1018847501985
A Novel Formulation of VIP in Sterically Stabilized Micelles Amplifies Vasodilation In Vivo
H. Önyüksel (2004)
10.1016/j.peptides.2004.05.013
Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP1–38 in pegylated phospholipid micelles
B. Ashok (2004)
10.1016/S0196-9781(02)00092-X
Interactions of human secretin with sterically stabilized phospholipid micelles amplify peptide-induced vasodilation in vivo
S. Gandhi (2002)
10.1016/j.peptides.2006.03.003
Human VIP-α: A long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension
H. Önyüksel (2006)
10.1016/B978-0-12-391860-4.00017-3
Nanoparticle-mediated treatment of pulmonary arterial hypertension.
W. Mosgoeller (2012)
10.1016/S0196-9781(03)00033-0
Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity
H. Önyüksel (2003)
10.1152/ajpregu.1999.276.5.R1359
Exogenous calmodulin potentiates vasodilation elicited by phospholipid-associated VIP in vivo.
H. Ikezaki (1999)
10.1016/S0196-9781(00)00161-3
Surface-active properties of vasoactive intestinal peptide☆
H. Önyüksel (2000)
10.1023/A:1012062424662
Development of a Novel Bioactive Formulation of Vasoactive Intestinal Peptide in Sterically Stabilized Liposomes
F. Séjourné (2004)
10.1016/j.ejpb.2008.04.015
Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
B. Stark (2008)
10.1152/ajpregu.1998.275.1.R56
Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch.
H. Ikezaki (1998)
10.1016/j.ijpharm.2009.08.013
Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect.
Junko Hanato (2009)
10.1016/S0969-8051(99)00062-1
Biodistribution of liposomal 131I-VIP in rat using gamma camera
E. Refai (1999)
10.1016/S0024-3205(98)00320-8
Sterically stabilized phospholipids attenuate human neutrophils chemotaxis in vitro.
U. Hatipoğlu (1998)
10.1007/s00210-007-0232-0
Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications
S. Onoue (2007)
Bioactive peptides and proteins in disease
E. Refai (2004)
10.1016/j.peptides.2007.04.009
Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD
S. Onoue (2007)
Semantic Scholar Logo Some data provided by SemanticScholar